Whose drug is it anyway: A Forxiga (dapagliflozin) AstraZeneca promotional webinar

Forxiga: Whose drug is it anyway?
Prescribing information and adverse event reporting can be found here.
Tuesday 21st September 2021, 7:00pm - 8:30pm

This live webinar will discuss how Forxiga 10mg can benefit your patients with Chronic Kidney Disease.

This webinar is for GB Healthcare Professionals only.

Q & A will follow this presentation

This promotional webinar has been organised and fully funded by AstraZeneca.

FORXIGA INDICATION

Type 2 diabetes mellitus
Forxiga is indicated, in adults, for the treatment of insufficiently controlled type 2 diabetes.

Heart Failure
Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction

Chronic kidney disease
Forxiga is indicated, in adults, for the treatment of chronic kidney disease.

GB-30632

Date of preparation: September 2021

Speakers

Professor Stephen Bain

Steve Bain is the Clinical Director of the Diabetes Research Unit, Swansea University and Medical Director for Research & Development for Swansea Bay University Health Board.

Professor Bain completed his undergraduate training at St John's College, Cambridge, and then was clinically trained at King's College Hospital, London. On qualifying in 1983, he went on to hold junior appointments in London, the East Midlands, and the West Midlands, UK. His research centred on the genetics of type 1 diabetes, and he was granted a Medical Research Council Lectureship. He became a Fellow of the Royal College of Physicians UK in 1996 and was appointed to a newly created Chair in Medicine (Diabetes) in the University of Wales Swansea in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Chief Investigator for several multi-centre trials investigating novel therapies for diabetes.

Professor Bain is the Diabetes Lead Clinician for the Swansea Bay University Health Board and chairs the Joint Clinical Research Facility in Swansea. He is currently Chair of the National Specialist Advisory Group (NSAG) for Diabetes in Wales.
Professor Indranil Dasgupta

Consultant Nephrologist
Consultant nephrologist, Heartlands Hospital Birmingham, Professor of nephrology & hypertension, University of Warwick; Honorary Secretary of the Renal Association UK; Co-chair of Association of British Clinical Diabetologists (ABCD) and the Renal Association Group; Member of the Research Working Party of British and Irish Hypertension Society; Expert Adviser, National Institute for Health and Care Excellence (NICE); Advisor International Society of Nephrology (ISN) Western Europe Board; Clinical Research Lead Division 2 (Renal, Stroke, CVD, Diabetes and Metabolic Diseases) for West Midlands in NIHR Clinical Research Network.
Dr. Andrew Frankel

• Working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995.
• Extensive experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease.
• Maintained a research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes.
• Published in relation to assessment of renal complications in people with diabetes and obesity.
• Has played a significant role in the development of UK national guidelines on the management of diabetes in the context of kidney disease.
• Joint editor of the UK Kidney Association guidelines on the use of SGLT2I in adults with chronic kidney disease
• Joint editor of the JBDS National Guidelines on the management of diabetes in people on dialysis
• Educational leader supporting the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training 2010 to 2013 and Postgraduate Dean for South London from 2013 and 2018.
Dr. JANAKA KARALLIEDDE

Dr Karalliedde is a Clinical Reader in the School of Cardiovascular Medicine and Sciences at King's College London and Consultant Physician in Diabetes and Endocrinology at Guy’s and St Thomas Hospital London.
He graduated with a distinction in medicine from the University of London and was awarded UK Medical Research Council Clinical Research Training Fellowship and PhD by the University of London for research on the pathophysiology and treatment of cardiovascular disease and kidney disease in diabetes. He has published widely in the subject of diabetic kidney disease and cardiovascular disease and has been awarded research grants from the UK Medical Research Council, Diabetes UK, European Foundation for the Study of Diabetes, National Institute for Health Research, and the International Diabetes Federation.
Dr Karalliedde is an active clinician, with expertise in managing patients with renal and cardio-vascular complications related to diabetes. He runs specialist clinics for patients with diabetic kidney and vascular complications at Guy’s and St Thomas Hospital and has led the development of cardio-renal community diabetes clinics in South London that are focussed on early identification and interventions in people with diabetes at high risk of cardiovascular and kidney disease.
Professor David Wheeler

David is Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients chronic kidney disease. Other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.
Dr. Peter Winocour

Consultant
Dr. Winocour is a consultant physician to the East and North Hertfordshire NHS Trust, appointed in 1993, and was Clinical Director for Diabetes and Endocrine services from 2008-2021. He qualified in 1979 and received his M.D. degree from the University of Glasgow, and undertook further training in Manchester and Newcastle. He is a past Chairman of the Association of British Clinical Diabetologists.
Dr Winocour previously co-ordinated national surveys of specialist diabetes services , was the Diabetes lead in the 2014 JBS3 guidelines on CVD prevention, and has led production of joint ABCD-Renal Association (RA) guidelines on diabetic nephropathy and organised successful joint ABCD-RA clinical meetings since 2013. Dr. Winocour’s research interest in diabetes and endocrinology has resulted in publication of over 100 original articles .